pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend here-
take account individu client circumst object need intend recommen-
dation particular secur financi instrument strategi particular client recipi report
must make independ decis regard secur financi instrument mention herein
cgm remain steep part adopt
implic
what technolog
implic
appendix chang estim
appendix addit detail notabl closed-loop insulin deliveri
margaret kaczor cfa blair overviewov last year major chang diabet devic sale driven solut
demonstr abil improv glycem control measur reduc-
tion time-in-rang introduct cgm start sea chang abil increas
time-in-rang million type patient unit state million
estim peopl diabet global cgm midst transform standard care
technolog advanc enabl improv clinic outcom payer respond
expand market access
insulin pump prove improv time-in-rang rel prior
standard-of-car multipl daili inject adopt grown modestli last year
start chang on-going innov industri primarili incorpor
cgm-enabl featur also good effort improv market access via innov form factor
report lay histori diabet devic innov paint pictur richer
futur peopl diabet abl achiev near-norm level glycem control
next five year increas incorpor artifici intellig machin
learn capabl train person algorithm would approach promis truli
artifici pancrea long holi grail medic technolog invest
see invest opportun across cgm insulin pump software-en diseas manage-
ment solut revenu growth top player remain elev dynam play
compani referenc report includ abbott beta bionic privat bigfoot biomed
privat tandem tidepool privat
diabet one largest health epidem unit state million peopl
affect billion annual healthcar cost associ diseas accord
center diseas control prevent cdc averag medic expenditur
type type diagnos patient estim time higher without
diseas emphas import glycem control improv patient outcom lower
cost burden global basi estim million individu diabet
result spend billion per year accord analysi
population-bas studi clinic econom signific global diabet epidem
led decad research best manag diseas although believ
enter one innov meaning period diabet manag
although devic adopt rise last sever year driven next-gener
product believ util still earli stage market view cusp
golden era clinic econom quality-of-lif data continu improv
dramat discuss evalu number player report public privat
becom valu creator diseas manag revolut recent continu
glucos monitor prove effect tool peopl diabet improv glycem
control turn support strong adopt technolog last sever year
insulin pump prove benefit diabet popul larg qualiti life
yet show level impact lag cgm peer growth
glycem control aim patient diabet technolog
margaret kaczor cfa blair adopt curv potenti maintain acceler alreadi high growth rate near
term sustain momentum three-plu year
believ cgm technolog well posit sustain strong market momentum support
under-penetrated insulin-depend market opportun next-gener technolog
improv market access cgm view remain one import input
varieti player affect patient care see opportun broader penetr
marketplac monet data gather whether partnership device-
maker big tech pharmaci payer
insulin pump believ market may near inflect point next-gener
closed-loop system meaning improv glycem control result acceler rate
patient adopt also believ chang dynam payer perspect move
pharmaci broader adopt type patient popul step-chang impact
growth taken togeth cgm insulin pump technolog view still earli phase
way background diabet diseas bodi unabl produc suffici insulin
prevent bodi properli regul glucos turn result unhealthi
level glucos bodi industri long focus hemoglobin level
track patient averag glucos level refin necessari diabet manag achiev
american diabet associ ada recommend less kid
still import part diabet manag new advanc cgm technolog
enabl in-depth real-tim track patient glucos level result
emphasi improv patient time healthi glucos rang refer time rang
maxim clinic outcom time rang also result lower level
juvenil diabet research foundat jdrf defin healthi glucos rang
mg/dl read mg/dl repres hypoglycemia low blood sugar
mg/dl hyperglycemia high blood sugar healthi glucos rang often use determin
success diabet technolog clinic studi refer throughout report
glucos level matter much uncontrol glucos level neg short-
long-term effect diabet patient obviou neg consequ poorli
control glucos level occur patient either hypoglycemia low blood sugar hy-
perglycemia high blood sugar extend period extrem level glucos danger
patient result immedi complic like organ complic heart failur
neurolog damag even death unaddress long glucos control also critic
long-term implic stem cardiovascular diseas eye damag skin condit
mani complic import glucos control minim long-term complic
demonstr sever studi one wide cite studi glycem
control prospect studi diabet patient unit kingdom sought
better understand link level long-term complic studi found
reduct level reduc diabetes-rel death reduc risk
microvascular complic reduc risk myocardi infarct among
sever clinic benefit
believ benefit proper glycem control well establish diabet care achiev
better glucos control bar new technolog must reach becom standard
care space discuss next section report believ cgm technolog
alreadi prove abil improv glucos control patient provid real-tim accur
conveni data patient use make more-inform insulin dose decis result
adopt cgm technolog grown sever year primarili benefit leader
space like abbott insulin pump shown benefit pa-
tient larg improv qualiti life yet show signific improv glycem
margaret kaczor cfa blair control still believ earli data next-gener closed-loop pump show potenti
improv glucos control among pump user look next-gener system lower
burden closed-loop technolog support adopt
lower reduc risk major complic
associ glycaemia macrovascular microvascular complic type diabet bmj
cgm set bar technolog diabet glycem control eas use
past two year innov glucos monitor technolog arguabl brought
impact advanc diabet manag recent histori specif cgm technolog
becom increasingli easi use introduct new featur like factori calibr
smaller transmitt elimin transmitt smart devic integr phone watch
pump improv sensor accuraci abbott main driver
innov opinion provid uniqu benefit product like abbott freestyl
libr g-seri sensor posit compani primari beneficiari
cgm adopt past sever year
featur provid patient real-tim glucos data flash glucos data case
libr accur enough use insulin dose decis turn elimin need
tradit blood glucos meter fingerstick read time clinic data contin-
ue demonstr benefit use real-tim continu glucos read manag
diabet sever studi shown use cgm technolog help reduc level
increas patient time rang ultim lower long-term complic rate regardless
insulin deliveri method patient usingmanu inject autom insulin pump
result cgm technolog experienc strong adopt among type diabet patient
result sever year market growth estim market growth acceler
confluenc tailwind acceler patient adopt lead growth
number cgm user even ad intens manag type patient type
popul market remain under-penetrated less adopt domest
previous mention believ abbott primari beneficiari
rapid rate adopt increas user base type patient
abbott grow user base type patient full year
margaret kaczor cfa blair cgm prove first half equat broad adopt improv glucos control
believ factorsnam clinic outcom eas use market accessar key
widespread adopt diabet manag technolog among type also type
estim ultim believ strong market adopt cgm technolog driven
introduct advanc cgm technolog improv patient eas use enhanc
clinic outcom believ cgm larg valid idea demonstr wide-
spread societi support consid gold standard diabet manag market
adopt technolog
patient believ confluenc factor late ab-
bott receiv fda approv libr system system new system
built clinic benefit previou meaning improv eas use elimin
fingerstick improv market access lower cost pharmaci access led ac-
celer rate adopt among type type patient type user
base like grew near estim type user base increas sevenfold
albeit much lower base
benefit use real-tim glucos read insulin dose decis seem intuit
sever clinic trial reinforc point demonstr use cgm technolog
lead significantli improv glucos control convinc data present
two larg randomized-control trial diamond gold trial show
cgm alon without use pump could significantli reduc level improv time
healthi glucos rang type patientsboth ultim improv long-term
diamond studi random clinic trial enrol type diabet patient
multipl daili inject mdi level patient random
diabet manag either mdi cgm mdi tradit blood fingerstick glucos meter
enrol cgm non-cgm arm respect primari endpoint
trial differ chang lab-measur level week compar
baselin data studi first present ada meet show cgm us-
er reach statist signific improv level compar control arm
cohort began trial mean level cgm arm reduc glycem level
percentag point week percentag point week compar favor-
abli control group mdi tradit fingerstick reader reduc glycem level
percentag point week percentag point week end cgm use
reduc level averag percentag point control arm
data also show cgm use result increas time spent recommend glucos rang
mg/dl cgm arm rang minut per day support
less time spent hypo hyperglycem rang respect
gold studi reinforc find diamond show similar statist signific im-
provement level ggm use trial enrol type diabet patient center
sweden random patient random either mdi cgm mdi fingerstick
glucos meter use week baselin level similar group
week level cgm group lower percentag point lower
glycem level fingerstick group lower percentag point lower
differ improv demonstr statist signific
improv lower glycem level standard deviat glucos level
mg/dl lower cgm group impli tighter glucos control potenti time
rang critic data patient diabet look reduc daili burden
diabet ultim improv long-term outcom better glucos control
clinic data support use cgm expand diabet societi start endors
technolog first-lin tool diabet manag support patient adopt
endocrin societi updat diabet practic guidelin co-sponsor ada late
call cgm gold standard diabet manag recommend type diabet
patient high normal level use devic nearli daili basi notabl
societi endors includ ada american associ clinic endocrinologist
aac advoc clinic benefit recommend regular patient use
believ posit clinic data one largest driver cgm adopt
beyond benefited/acceler next-gen product well info support
consist market growth rate clinic case cgm technolog becam
concret physician patient drawn technolog improv long-term health
insulin pump studi demonstr patient benefit improv qualiti life
believ clinic data mix best come improv glycem
control specif notabl random control trial demonstr
abil insulin pump significantli improv glycem control patient registri often fail
show benefit insulin pen usag mostli use conjunct cgm
result insulin pump adopt histor grown well cgm market midsingl digit
patient look increment conveni slowli adopt technolog still believ
next-gener closed-loop system may play critic role demonstr clinic valu
better cgm part use cgm technolog expect could support acceler
market adopt insulin pump
next-gener cgm offer half equat enhanc featur lower
clinic data societi endors provid broad tailwind cgm adopt last
month next-gener cgm technolog usher new era advanc featur
importantli meaning reduc burden cgm use spur new level market
adopt market histor grown annual ad
user per year estim market grew ad
patient respect acceler cgm adopt coincid innov
product launch space seen thu farfreestyl libr late earli
coupl year clinic data reinforc import cgm use
margaret kaczor cfa blair import featur launch mostli nonadjunct label
mani featur culmin one new product late market
notabl innov timelin cgm adopt
cgm gold standard
expect launch
note total cgm user includ type type patient
sourc william blair estim compani file
highlight meaning cgm enhanc pave way
cgm becom standard care diabet manag
nonadjunct label late receiv fda approv nonadjunct label-
ing mobil system usher new standard cgm devic nonadjunct
label allow patient make insulin-dos decis base cgm read without
need take confirmatori fingerstick glucos read elimin need
fingerstick read user still need calibr everi hour drastic
lower fingerstick requir ultim reduc daili burden diabet manage-
ment cgm user
big leap cgm technolog made possibl innov sensor accu-
raci dexcom boast mean absolut refer differ mard
single-digit mard time still one accur system today
receiv fda approv nonadjunct label particip fda advisori panel
meet agenc look better understand risk benefit label
end panel vote favor nonadjunct label lead fda approv late
factori calibr introduct factory-calibr set anoth standard
technolog elimin need fingerstick glucos read accord ada type
patient use fingerstick blood glucos meter requir averag six eight read per
day signific burden requir patient prick finger draw blood everi
time want glucos read introduct factory-calibr elimin
need fingerstick measur late abbott first receiv approv
factory-calibr devic fda clearanc freestyl libr system
follow close behind approv march system huge leap
diabet care meaning reduc daili burden diabet manag
integr smart devic integr cgm read smart devic like
iphon appl watch streamlin diabet care make data access
conveni patient caretak earli cgm smartphon app limit still
reli connect system receiv introduc import featur like share
real-tim cgm data other especi import children elderli access
glucos level histor chart smartphon today system build featur
even commun directli sensor transmitt effect elimin need
receiv anoth increment step toward simplifi diabet manag
allow patient leav home one less item need manag diseas
first launch smartphon connect devic bluetooth
receiv later updat app includ appl watch integr although system still
requir receiv purchas unit state abbott freestyl libr also requir
purchas receiv unit state nfc-enabl smartphon scan
libr sensor download current histor eight hour glucos read
smart devic integr abbott
dexcom iphon appl watch
abbott iphon app reader
sourc abbott compani websit
pharmaci coverag power evolv driver unit state distribut cgm
technolog pharmaci channel game changer patient significantli
reduc barrier adopt specif pharmaci channel potenti mean-
ing lower administr burden associ cgm order patient
doctor even lower cost patient lower co-pay sometim lower
list price expect futur gener cgm technolog elimin need
transmitt receiv allow patient purchas sensor regular basi
pharmaci thu streamlin purchas process know dexcom
plan elimin transmitt late abbott alreadi elimin
transmitt libr time go receiverless still unknown
margaret kaczor cfa blair physician would increas cgm prescript pharmaci benefit
recent cgm technolog classifi durabl medic equip dme
process burdensom dme pathway pathway take four
week medic devic compani work patient payer physician distributor
collect inform fill proper paperwork even ship system
patient long burdensom process patient physician also
tend avoid difficult process possibl market research impli
certif medic necess requir payer
abbott first cgm player make meaning progress pharmaci channel
launch freestyl libr launch abbott dedic pharmaci channel
leverag libr rel low price point gain traction channel believ
major abbott freestyl libr user purchas sensor pharmaci chan-
nel today work payer secur pharmaci coverag
gain notic traction patient benefit clearer often
lower co-pay order pharmaci estim sell
sensor nearli lower asp pharmaci channel reduc barrier
adopt togeth avail cgm technolog abbott
pharmaci channel help increas physician prescript cgm lower barri-
er adopt patient
overal innov usher new era diabet manag center leverag
cgm data improv glycem outcom lower daili burden diabet manage-
ment believ insulin pump includ first-gener closed-loop system thu far
demonstr similar eas use clinic outcom cgm technolog limit
adopt insulin pump last five year diabet still believ
next-gener closed-loop system introduc featur capabl meaning lower
burden pump use subsequ unlock anoth larg portion remain
patient use pump discuss later report
estim number cgm user grown past four five year
result adopt among million insulin depend patientsimpli
fulli acceler greater full year support next-gener cgm system
accompani meaning advertis invest abbott
improv eas use lower barrier adopt improv market access type
patient histor largest adopt cgm technolog new cgm
user type adopt acceler benefit devic featur cost make
almost new user expect trend continu potenti acceler
next sever year
insulin-depend type patient long focu diabet industri given potenti
doubl treatabl market opportun recent technolog innov
market access win market becam real opportun result acceler adop-
tion believ approv abbott freestyl libr system arguabl
impact catalyst drive type adopt meaning enhanc eas use rel low
cost even reimburs factory-calibr devic libr first fda-approv
glucos monitor elimin need fingerstick calibr meaning reduc
burden cgm usag also diabet manag whole abbott launch
cgm remain steep part adopt curv
margaret kaczor cfa blair libr system cost competit cgm system heavili use pharmaci channel
rather dmeboth import market access win help open door
type patient regardless insur coverag type histor poor coverag
featur previous discuss broad tailwind cgm adopt
highlight specif driver type market today futur
expect adopt cgm technolog type insulin-depend popul larg
driver growth domest market make new patient add
next two year least believ libr help acceler market introduct
easy-to-us reason afford sensor believ player notabl
also benefit type cgm usag next three-plu year sinc launch libr
also launch factory-calibr cgm improv eas use start make
progress similar market access initi like secur pharmaci channel coverag elimi-
nate burden dme lower cost patient abbott also heavili focus
pharmaci channel culmin compani effort broadli expand market
access type patient cgm still believ price point continu limit
type adopt patient insur coverag low number compar type although
compani highlight progress expand reimburs last sever quarter
term form factor dexcom system expect late earli help close
gap libr system offer fulli dispos sensor elimin need
transmitt two cgm provid believ
requir fingerstick calibr larger/mor intrus devic lack pharmaci ac-
cess leav abbott primari beneficiari type space
despit explos type adopt last year nearli eightfold increas user
estim less intens manag type patient use cgm
technolog previous highlight believ technolog market access reach
inflect point capabl sustain strong adopt market therefor estim
type patient adopt make new user
respect although still result adopt exit
type patient
histor
main adopt cgm
type adopt
acceler expect
continu
abbott libr
one main reason
type acceler
factori calibr
low cost key
type adopt
estim cgm user unit state exit
type type believ leav suffici room three year
continu momentum cgm adopt unit state alon impli adopt
among type diabet adopt among type type insulin-depend patient
unit state despit signific rise cgm adopt still see three year
plu growth primari cgm player like abbott support addit product
innov think dexcom smart pump power cgm continu improv
market access lower price pharmaci channel access adopt among insulin-depend
type patient specif believ type patient adopt still earli inning less
type use cgm technolog exit despit proven clinic benefit
walk assumpt market model leav us confid
opportun sustain growth cgm adopt
given earli stage abbott freestyl libr launch compani larg impress
user base market build assess two differ scenario first scenario assum abbott
report patient base experi typic patient churn consist compani comment
second allow higher patient churn typic new technolog
domest cgm market exit use data cdc estim
million peopl diabet manag intens insulin therapi exit
first scenario analysi assum libr patient number line manag com-
mentari result type market penetr year-over-year
total intens manag insulin-depend patient popul penetr
year-over-year exit
compar second scenario assum patient attrit libr
type market penetr year-over-year total insulin-
depend popul penetr year-over-year full year
scenario analysi result two differ market penetr
level approxim basi point apart could
repres million market remain larg
under-penetrated scenario
sourc william blair estim compani file
market remain untap exit
scenario patient base face valu first scenario assum libr user base
line abbott guidanc patient patient
manag note previous user roughli patient
type remain type assum exit
total instal base user user
support higher sensor attach rate eas suppli constraint sensor lastli
assum end user line compani guidanc
go forward estim abbott grow libr instal base
respect exit approxim user
growth estim larg line manag long-term guidanc
growth respect result activ
user end despit strong growth top two player result mid-
high-teen market growth estim type market penetr
insulin-depend market opportun penetr exit expect
market penetr increas meaning next three year estim
still billion untap market opportun type alon exit look
entir insulin-depend market opportun unit state estim billion
scenario patient base churn second scenario factor
churn rate abbott freestyl libr user base potenti captur activ histor
 cgm user base estim approxim churn rate user base
doubl estim libr given system low start-up cost patient get
receiv free leav patient less invest cgm decis
libr churn scenario assum figur scenario except libr patient base
lower year account patient attrit result total
activ user end respect
impli market growth scenario mid- high-teen rang next three
year estim result type insulin-depend patient hav-
ing adopt cgm exit result untap type market opportun
implic dexcom
pure-play cgm technolog analysi focu though note
expect cgm manufactur benefit market growth well includ assump-
tion broader market model
said believ remain well posit meet exceed compani guid-
anc overal sale compound-annual-growth-rate initi provid late support continu
momentum cgm market awareness/demand best-in-class technolog on-going
shift pharmaci channel cgm market model dexcom-specif estim suggest
compani grow domest user base compound annual rate slightli
next three year even libr user base grow rate suffici room
anoth two three year growth intens manag core popul alon
mention earlier math total intens manag domest cgm opportun would
approxim penetr exit leav greater billion market opportun
grow includ expans new market opportun like non-
intens manag type profession market among other believ interna-
tional also larg growth driver compani peer patient access improv
billion billion look insulin-depend patient exit
margaret kaczor cfa blair believ could acceler user adopt cgm technolog launch
verili sensor increas market effort either peer histori-
calli driven broad market growth expect system expect late earli
help close gap abbott libr system offer fulli dispos sensor elimin
need transmitt ultim provid tailwind patient addit
help bring patient sidelin potenti increas market share rel
libr lastli believ abl ramp market initi
beyond execut doubl manufactur capac end
allow compani aggress offens cgm market anoth
tailwind patient adopt believ cgm remain steep part adopt curv
remain well posit primari beneficiari space
point cgm experienc rapid uptak adopt recent insulin pump adopt
rel stabl use roughli one-third type diabet type diabet
exit still believ product innov roadmap pump market never
dynam adopt trend acceler although question remain pen-
etrat peak specif expect next-gener insulin pump provid improv
clinic outcom drive significantli broader use
pump autom featur develop varieti player still like fall short
fulli close loop pump anticip patient eat lot carbohydr
dramat reduc number time per day patient must take action manag
diabet algorithm develop better job patient an-
ticip glycem excurs high low improv short- long-term outcom
featur launch believ clinic data develop support acceler
adopt pump patient
background insulin protein hormon help regul amount sugar
bloodstream type diabet make insulin insulin-depend type
diabet typic either resist effect insulin produc enough insulin maintain
normal glucos level type initi treat varieti oral medic
two way deliv insulin insulin pen syring insulin pump two-third
type patient today deliv insulin pen one two long-act inject three
rapid-act inject daili insulin-depend type use pen
one-third type insulin-depend type deliv insulin pump
pump deliv insulin two way constant deliveri basal rate insulin day
base rate irrespect food intak occasion bolu dose need typic
around meal still clinic benefit pump mix large-scal random
control trial rct suggest statist signific improv outcom standard
care summar recent sensor-aug insulin pump
suggest clinic back pump start shift favor next-gener
technolog launch
research suggest afford patient want simplic eas use
margaret kaczor cfa blair insulin pump improv vs mdi improv qualiti life
pump penetr increas modestli last year usag type patient
approxim prior year growth pump market
constrain increment improv pump technolog technolog improv
includ miniatur pump ad bolu insulin on-board calcul provid
therapi remind offer download softwar updat featur touchscreen capabl
next wave innovationparticularli advent sensor-aug pumpsi focus
ad valu patient physician prescrib reduc burden therapi
expect launch new products/partnership acceler pump usag
roughli one-third penetr rate today perhap basi point per year next
two year end decad expect usag grow basi point
per year new innov come market pump therapi becom compel option
repos trial one random control trial compar clinic benefit
insulin pump standard care multipl daili injector mdi insulin pen trial
follow patient eight center unit kingdom two year partici-
pant random insulin pump mdi therapi arm respect start
studi patient poorli control averag arm improv
level expect insulin pump show statist signific improv
lower level compar mdi
studi also control patient educ provid five-day train cours pump
mdi random ensur particip equal understand benefit
maintain stabl glucos level trial use dose adjust normal eat dafn
curriculum design nation servic ensur patient receiv qual-
iti equal educ enrol
howev adjust center cours baselin mean differ
chang baselin statist signific show percentag point
differ month favor insulin pump arm result similar
follow-up show percentag point percentag point
mean differ baselin favor insulin pump neither
repos trial also track number patient achiev recommend level less
equal better understand insulin pump mdi effect reach
society-recommend glucos level month percentag patient achiev
level less equal insulin pump mdi respect
calcul odd ratio statist signific month valu
result month month similar odd ratio show statist
advantag insulin pump
insulin pump user see signific differ lower level show
signific improv qualiti life measur diabetes-specif qualiti life dsqol
score dsqol scale scale point survey use assess diabet qualiti life
focus individu treatment goal satisfact treatment success diabetes-rel
distress month insulin pump user demonstr improv total
dsqol score compar improv mdi group differ
statist signific support signific quality-of-lif improv
leisur time restrict daili hassl manag function diet restrict
mean differ chang
improv favor pump
percentag patient
insulin pump demonstr numer improv glucos control show statist
mean improv dsqol score baselin
leisur time restrict daili hassl function
highlight data exchang state type diabet manag outcom
registri type diabet patient publish data
studi less formal control trial demonstr margin improv
glycem control lower insulin pump user still fall short benefit seen
use cgm even patient use pump mdi user demonstr insulin-
pump-onli user exchang consist reach lower level injection-onli
user still inject user also use cgm technolog consist reach better glycem
outcom insulin-pump-onli user believ reinforc concept insulin pump
alon prove meaning benefici cgm technolog consist shown
improv glycem control regardless insulin deliveri method also note
insulin pump compani may retrospect data glycem outcom user base like
highlight past believ pump industri need well-control
fulli demonstr benefit pump alonesometh histor miss
margaret kaczor cfa blair exchang outcom technolog use
state diabet manag outcom exchang
insulin pump user
control lower
mdi user
said pump user
see improv
glycem control
compar mdi
cgmreinforc
import cgm rather
pump improv
hybrid close loop demonstr potenti insulin pump
hybrid closed-loop hcl insulin pump first major step toward develop fulli closed-
loop system histor refer artifici pancrea system use
real-tim glucos data automat adjust insulin basal rate goal improv
patient glucos control sensor-aug pump sap alreadi introduc featur
like cgm integr low-glucos suspend hcl system first time insulin pump
automat make dose decis increase/decreas basal rate beyond simpli suspend
resum insulin deliveri hcl system requir manual intervent bolu decis
typic around mealtim loop fulli close nonetheless approv launch
first hcl system semin moment diabet manag
open regulatori pathway advanc system
reach fulli closed-loop pump system difficult given high variabl glucos
insulin respons coupl need person algorithm rapidli safe
react user uniqu need sever on-going effort develop fulli closed-loop
insulin pump system ventur start year ago first closed-
loop system still expect market anoth two three year still believ
mani benefit closed-loop system without close loop drive
adopt expect next-gener pump system introduc new autom featur
case build prior system later report provid outlin import featur
system expect launch
potenti better glycem control demonstr earli hcl trial shown
significantli lower level improv time healthi glucos rang usual mg/
dl compar tradit pump therapi alon still expect next-gener pump
potenti improv clinic outcom lessen daili burden closed-loop use
introduc new advanc featur autom insulin-dos decis specif
expect improv softwar greater cgm compat reduc daili burden
manag closed-loop system new advanc featur auto bolu correct
improv user pump experi creat reliabl trustworthi system
one earlier multicent random control trial assess benefit insulin-onli
hcl technolog use artifici beta cell type diabet publish
part jdrf artifici pancrea project app patient adult children/
margaret kaczor cfa blair adolesc enrol trial use hcl system week sap similar
amount time assess outcom two period primari endpoint
trial time spent target glucos rang mg/dl adult mg/dl
children/adolesc patient use abbott freestyl navig cgm connect dana
diabecar insulin pump run hcl algorithm design cambridg univers research
team refer florenc data trial broadli posit advanc pump
outlin florenc system fda approv test beta phase technolog
thu expect next-gener system improv outcom trial
make improv eas use includ easier/mor accur advanc algorithm
use hcl system adult spent day within target glucos level
percentag point time rang use sensor-aug pump
therapi alon children adolesc saw similar improv spent
day rang repres improv compar sap therapi alon
averag glucos level adult children/adolesc significantli
lower use hcl system specif adult record averag glucos level mg/
dl lower time sap children/adolesc record averag
glucos level mg/dl lower sap
use artifici beta cell type diabet glycem outcom
percent time glucos level
sap group
time spent within
rang compar
sap group
note sensor use
trial sever
year old believ
inferior
use artifici beta cell type diabet
anoth semin trial hcl space pivot trial reinforc
benefit hcl technolog significantli lower level improv time rang
trial enrol patient adolesc adult use insulin pump
therapi least six month nine site one center israel enrol patient
underw two-week run-in phase use manual modethi
period use baselinefollow three-month period auto mode
would evalu safeti hcl system patient use insulin pump
connect guardian cgm power compani hcl softwar refer
auto mode
three-month use auto mode hcl adult adolesc experienc sever
meaning improv clinic outcom especi compar baselin manual
mode characterist specif trial found auto mode result follow
significantli increas time spent healthi glucos rang mg/dl
two-week baselin period patient use manual mode adult adolesc
within healthi glucos rang time respect three month
use auto mode hcl adult adolesc increas time rang
respect
significantli lower level two-week baselin period adult adoles-
cent record level respect three month use auto
mode hcl adult adolesc decreas level
significantli decreas time spent hypoglycemia mg/dl two week
baselin period adult adolesc spent hypoglycemia respect
three month use auto mode time spent hypoglycemia lower
adult adolesc respect adult use auto mode spent
time hypoglycemia adolesc time
percent time glucos level rang
percent time glucos mg/dl hypoglycemia
pivot trial enrol patient site use
manual mode baselin period auto mode hcl
month
benefit auto mode includ
significantli time spent healthi glucos rang
significantli reduc level despit baselin
period includ sap use
significantli less time spent hypoglycemia mg/dl
glucos outcom in-hom use hybrid closed-loop insulin deliveri adolesc adult type diabet
first-gener closed-loop technolog cumbersom widespread use
medtron hcl system commerci avail fda approv
system late semin event industri usabl suffer usual plight
first-gener technolog user physician feedback auto mode consist
point overwhelm daili burden frequent alert fingerstick calibr sensor
error set chang carb count among sever other
highlight data present year ada meet found nearli user
stop use auto mode entir within month given daili burden associ
system specif observ studi patient saw user
complet stop use auto mode month month respect sensor
reason use featur acknowledg small studi believ
highlight today hcl technolog meaning acceler market adopt
pump today system burdensom broad adopt
month
stop use
top reason
mode sensor
issu select
user
use auto mode
use auto mode time
clinic experi present ada meet
manag diabet alreadi extrem burdensom task patient low toler-
anc make diseas burdensom even improv outcom exhibit
highlight differ alert happen multipl time day outlin
user manual requir action patient time day night ensur
auto mode remain activ mani alert caus guardian sensor
approv factori calibr requir two calibr per day non-
adjunct label requir addit calibr meal consist feedback
survey data aforement studi found user stop
use auto mode sensor
readi checklist
correspond error action
need enter auto mode
errors/act auto mode
outlin user guid
calibr requir perform fingerstick calibr sensor
bg requir perform fingerstick enter new bg valu
wait enter bg wait pump prompt fingerstick bg
process bg wait fingerstick bg process
auto mode turn turn auto mode smartguard menu
sensor readi check enter transmitt id move
transmitt closer pump check sensor still insert check
transmitt still connect none work redo connect
sensor turn sensor set menu
airplan mode turn airplan mode util menu
bolu progress wait bolu complet stop bolu auto mode
deliveri suspend activ auto mode deliveri
suspend treat low bg necessari instruct physician
carb ratio set enter carb ratio bolu wizard
temp basal rate activ temp basal rate
activ insulin updat activ insulin updat may take
hour complet activ time
auto mode warm auto mode gather info insulin deliveri
histori person automat insulin deliveri
look next-gener system expect see meaning improv patient eas
use top new advanc featur improv eas use lessen daili burden advanc
pump technolog believ next-gener system abl support next level
insulin pump market adopt highlight import area believ
pump manufactur improv closed-loop system lower burden technolog
sensorsfactori calibr improv accuraci reli medtron guard-
ian sensor requir minimum three four fingerstick calibr per day although
real-world feedback suggest patient ask calibr sensor sever time
recommend system calibr prompt patient knock
auto mode prompt action usual requir use benefit hcl algorithm
need fingerstick calibr throughout day burdensom patient
voic frustrat excess alerts/notif receiv prompt
take action disturb day believ calibr requir alert
mainli driven poorli design softwar higher mard guardian sensor
hcl algorithm account inaccuraci err side
caution outsid certain rang prompt anoth fingerstick calibr
expect next-gener hcl system address sensor inaccuraci frequent calibra-
tion either new cgm system compat accur system
alreadi commerci avail former remain dedic improv
accuraci calibr requir sensor extens effort cgm
system asid compani like abbott senseon alreadi
commerci meaning accur cgm system although still requir
sever fingerstick calibr per day cgm compani alreadi partner
major hcl develop bring next-gener system market
manual bolu calcul requir patient manual calcul enter carb
eat meal deliv insulin bolus name hybrid closed-loop come
sinc still requir manual intervent activ manag diabet patient
gener accustom carb count whether insulin pump use mdi
requir add anoth level complex potenti user error elimin need
manual bolu calcul difficult given wide varieti factor affect blood
glucos level accord diatrib on-line public focus diabet patient
differ factor affect glucos level mani factor abl rais
lower glucos level depend circumst person
given challeng expect manual bolus elimin sever year
say meaning improv exampl tandem control-iq
hcl system expect deliv automat bolu correct dose limit inaccuraci
manual carb count potenti make manual bolu deliveri less stress patient
hcl system plan simplifi bolu process elimin need count
carb instead select preset meal option food emoji size meal hcl
algorithm becom advanc reliev burden manual carb count-
ing support patient adopt hcl pump
lack pump sensor algorithm compat remain steadfastli dedic
creat full diabet manag solut rather individu product end
surprisingli requir use insulin pump sensor even
on-board algorithm drive auto mode believ limit factor hcl
technolog sinc patient strong prefer pump cgm technolog may
want convert full ecosystem
ultim believ interoper hcl system support adopt insulin
pump patient use prefer cgm pump algorithm enjoy ben-
efit hcl technolog fda help lay foundat possibl
establish new regulatori framework integr cgm system icgm altern
controller-en ace insulin pump autom insulin dose aid system
new regul lessen burden bring high-qual product marketprimarili
pathwayit also enabl icgm ace aid product work unison
regardless whether receiv fda approv togeth
outdat burdensom pump surprisingli today hcl system come quirk
common first-gener technolog includ rel challeng user interfac ui
creat burdensom user experi medtron revolut term
new featur first receiv hcl approv pump design date back far
minim led industri advanc featur
still reli consid outdat burdensom ui small screen mechan
button believ hassl patient especi consid host alerts/notifica-
tion patient get daili basi need easi navig system ui
develop next-gener technolog improv user experi
compani like tandem alreadi easy-to-us system commerci avail compani
like tidepool look revolution user experi replac receiv intui-
tive easy-to-us smartphon app next-gener system critic reduc
burden associ hcl use ultim support widespread adopt insulin pump
medtron approv
launch select intern market
system longer
featur nearli
control-iq pivot reinforc clinic benefit closed-loop system
american diabet associ meet data present nation institut
health intern diabet close loop trial featur tandem hcl control-iq system
compani use random control pivot trial data support regulatori submis-
sion fda highlight control-iq achiev meaning better glucos control
non-hcl user support potenti fda approv system fourth quarter
line tandem guidanc control-iq launch softwar upgrad nearli
exist tandem slim user mani receiv updat free avail
pre-instal slim pump approv expect tandem control-iq system
second commerci avail closed-loop system behind medtron howev
first system autom correct bolus
nih fund trial follow patient six month assess safeti efficaci
system patient random either control arm use sensor augment pump
therapi hcl arm use control-iq softwar tandem slim
insulin pump dexcom sensor
result trial broadli posit control-iq patient spend significantli
time target glucos rang spend less time hypo- hyperglycemia reduc
level control-iq user report posit eas use satisfact score
hcl platform highlight potenti advantag difficult-to-us technolog avail-
abl today believ data set reinforc clinic benefit use closed-loop technolog
improv glucos control diabet patient ultim could support broad adopt
insulin pump highlight key data believ reinforc thesi
significantli increas time spent healthi glucos rang week control-iq
arm spent averag time target glucos rang better
sap group target rang time
significantli lower week control-iq arm saw significantli lower
level approxim lower sap group reach aver-
age level pivot public yet avail fulli understand
variabl glucos level believ averag glucos level closer shown
control-iq impli nearli half patient achiev ada recommend
level arm studi start averag level mean
control-iq arm show numer improv sap group larg line
begin valu week
significantli less time hypo- hyperglycemia week control-iq arm spent
significantli less time hypoglycemia mg/dl spend studi low
glucos rang compar sap group numer
differ seem small impli control-iq user would spend fewer hour
hypoglycemia per year control-iq arm also spent less time hyperglycemia mg/
dl spend time high glucos rang compar sap group
time rang mg/dl
demonstr slim enhanc user experi
patient control-iq pivot trial also show high satisfact system respond
posit post-trial questionnair eas use perceiv efficaci among factor
burden use first-gener hcl result rel low time auto
mode meaning number patient longer use advanc pump featur believ
posit feedback patient control-iq trial reinforc potenti slim advanc
pump featur help acceler market adopt advanc insulin pump
time spent close loop overal control-iq user oper close loop
studi time wherea sap arm use time note patient
control-iq arm ask remain close loop extend period
long four week wait softwar updat control-iq algorithm
result patient neg affect time spent within close loop impli
result could even higher report also note sap group
spent studi time cgm activ impli downtim cgm system
feedback ada suggest downtim larg due patient switch sensor taken
context impli control-iq arm spent cgm access studi time
hybrid close loop
nih pivot trial use control-iq design head-to-head trial
publish studi believ data demonstr meaning user
enhanc control-iq system support widespread adopt insulin
pump technolog specif control-iq time spent oper within close loop
margaret kaczor cfa blair compar favor pivot trial patient spent studi
time oper auto mode close loop recent highlight softwar updat
reduc number blood glucos calibr request expect
forc patient auto mode less often believ new softwar updat
get real-world result time spent auto mode although remain skeptic
sinc system still use guardian sensor still earli launch gather mean-
ing feedback either way new goal greater time auto mode still
control-iq reinforc advanc tandem made improv insulin pump use
high satisfact control-iq studi also survey hcl user technolog accept
system receiv posit result show better four differ topic
includ eas use score use score trust score desir
continu use system trial score easi comparison
data still believ previous highlight observ studi user
stop use auto mode month reinforc point slim made meaning
enhanc lower daili burden advanc insulin pump enhanc softwar
incorpor believ meaning better cgm lower mard factor
calibr dexcom
eas use
desir continu use
overal believ improv user experi control-iq result intuit
insulin pump slim reliabl less burdensom cgm dexcom sup-
port power clinic proven algorithm typezero/control-iq shortli june
present control-iq pivot trial tandem file pma approv expect fourth quarter
approv provid addit inform compon control-iq
system believ provid user enhanc diabet manag solut
dexcom icgm compat tandem ran control-iq pivot trial reli glucos
read dexcom intend commerci system configur
launch believ integr dexcom give slim patient meaning ad-
vantag reduc daili burden closed-loop manag specif
factory-calibr sensor nonadjunct label meaning reduc elimin
number fingerstick calibr need remain within close loopsometh believ
demonstr time spent rang control-iq pivot trial
term interoper tandem plan incorpor sensor achiev icgm
design softwar updat exist user base expect abbott freestyl libr
like next icgm approv system unit state would provid slim
user anoth factory-calibr potenti much less expens cgm solut run
hcl system libr expect approv icgm sensor tandem
need run new clinic trial simpli need push softwar updat user
enabl libr compat still tandem said intern develop test
softwar upgrad may take month deliv patient believ integr
dexcom futur icgm sensor meaning enhanc capabl
lower daili burden diabet manag provid tailwind market adop-
tion advanc pump technolog
enhanc pump design slim pump market sever year
tandem design system consum focu result believ
posit less burdensom experi insulin pump user tandem latest-gener
pump slim rel small pump smaller pump
color touchscreen recharg batteri bluetooth connect waterproof case
upgrad softwar believ import featur patient give slim
pump modern feel similar smart devic could reduc burden diabet
manag improv patient complianc
improv bolu deliveri much like medtron control-iq requir patient manual
calcul meal-tim bolus carb calcul load insulin pump control-iq take
step toward lower burden bolu calcul incorpor automat bolu
correct featur deliv addit bolu unit algorithm determin glucos
level rise target rang exampl user miscalcul number bolu
dose need follow meal control-iq abl detect glucos level
rate chang deliv addit bolus correct error system still
requir patient enter mealtim bolus believ increment lower burden
bolu deliveri improv outcom reduc amount precis requir
bolu calcul sinc control-iq help correct user inaccuraci bolu calcul
last five year insulin pump market grown well rate cgm
adoptionpump market growth typic report mid- high-single-digit rang
given lack clear clinic benefit barrier entri insulin pump rel cgm higher
cost result insulin pump adopt remain within type patient
last five year reach exit market growth among type patient
slightli higher type larg smaller base patient
insulin-depend type patient adopt pump technolog among million
insulin-depend patient unit state estim use insulin pump
technolog exit leav ampl room year strong acceler market growth
expect next-gener closed-loop technolog coupl improv market access mostli
move pharmaci channel elimin up-front cost help bring
patient sidelin acceler market growth bull case scenario addit detail
later report estim total market growth pumper acceler
compar histor growth mid- high singl digit seem like
small increas would result increas number new pumper ad
everi year ad roughli pumper histor
implic market growth
margaret kaczor cfa blair insulin market growth patient ad market growth bull case scenario
sever year
expect next-gener
hcl system start
adopt pump
bull case scenario
think market growth
acceler
high singl digit
next year could
acceler patient add
sourc compani file william blair estim
what technolog
despit acceler pump adopt estim market remain heavili underpen-
etrat type insulin-depend patient use pump technolog
exit impli nearli million insulin-depend patient use pump
technolog result greater billion untap market opportun exit
expect leav ampl room strong momentum five-plu year potenti
acceler new technolog lower daili burden pump usag clinic outcom
improv advanc algorithm tighter glucos control market access im-
prove either better reimburs lower barrier adopt pharmaci channel
up-front cost next section outlin mani technolog develop
import step major pump player along way
believ diabet industri begin could multi-year innov cycl
insulin pump technolog start tandem control-iq late system ex-
pect improv clinic outcom user experi drive sustain pump
adopt vastli under-penetrated pump opportun expect sever iter
system along way import right system bring us closer
ultim goal elimin greatli limit amount manual interact need
make decis insulin dose
follow outlin believ meaning mileston reach
fulli closed-loop insulin system outlin larg line popular six-step roadmap
juvenil diabet research foundat jdrf establish although fo-
cuse commerci mileston along pathway still outlin jdrf roadmap
lead person fulli closed-loop system capabl elimin manual input
user see signific benefit achiev fulli closed-loop system believ
multipl near-term product still requir manual input improv outcom
drive market adopt
margaret kaczor cfa blair outlin linear time mean insulin pump compani de-
velop product specif certain featur exampl skip sap mileston
focu clinic effort launch first hybrid close loop achiev
compani plan move progress closed-loop system
industri advanc system still three year commerci
believ near-term launch capabl provid enhanc clinic benefit user
experi drive broader market adopt insulin pump
 approv timelin notabl loop system
directli onto pump allow user see glucos level insulin dose one
system sap use cgm data make automat insulin dose decis
laid foundat pump cgm connect integr part closed-loop
system first sap launch year ago use sap featur limit
inaccur burdensom cgm technolog time
ii low-glucos predict suspend pump cgm data integr
insulin pump industri start shift focu use real-tim glucos level make
autom insulin decis system gener narrow scope decision-
make limit basal dose develop anoth import step
reach closed-loop system repres first time insulin pump could chang
therapi patient first system commerci categori low-glucos suspend
system reactionari devic would suspend insulin dose user glucos
level fell certain glucos threshold
next-gener system use advanc algorithm predict base histor glucos read-
ing user glucos level would minut ahead time suspend
resum insulin deliveri base predict featur often refer predict
low-glucos suspend plg plg system design improv patient time healthi
glucos rang prevent reach hyper- hypoglycemia although suspen-
sion/resumpt insulin often enough maintain glucos target henc need
advanc system still plg system first time insulin pump could
predict patient futur glucos level also make insulin decis base valu
minim one first plg system wide avail launch
select intern market start much like today minim system
reli sensor smartguard softwar make insulin decis user
ultim bypass commerci launch unit state decid
instead focu clinic regulatori effort launch
margaret kaczor cfa blair tandem basal-iq launch unit state late run tandem slim
pump dexcom sensor tandem intern develop plg algorithm
system abl predict glucos level minut ahead time suspend insulin deliveri
two hour resum deliveri glucos level return normal level
slim upgrad softwar tandem abl push basal-iq exist user base
without need upgrad hardwar allow patient use featur almost imme-
diat overal basal-iq tandem first step predict glucos level make
insulin decis base read experi help compani develop
next gener advanc pump featur control-iq
hybrid close loop hcl today hcl system advanc system com-
mercial avail today system leverag predict capabl plg system
titrat basal insulin dose everi five minut base real-tim predict cgm read
goal hcl system keep user glucos level within target rang adjust-
ing basal dose suspending/resum basal deliveri need mark import
step toward fulli closed-loop system first time insulin pump abl make
automat dose decisionsrath suspend/resum decisionsbas predict
real-tim glucos level
hcl system ad new level autom patient basal deliveri system
still requir manual input bolu deliveri henc name hybrid close loop
common bolu deliveri occur around meal requir user estim number
carb within meal subsequ mani bolu unit insulin need coun-
teract come rise glucos level mani insulin pump incorpor bolu calcul
help user estim number insulin unit requir base estim carb figur
still number factor could affect glucos level outsid carb diatrib
estim total differ factor ultim could lead sub-optimal glucos control
next-gener system focu elimin inaccuraci manual input
also leverag smart algorithm fine-tun glucos control
sourc diatrib william blair
stress ill
frequenc glucos check
level fitness/train
time day
food insulin time
minim fda approv mileston diabet
manag sinc first fda-approv devic automat make insu-
lin dose decis user today minim still commerci
margaret kaczor cfa blair avail hcl system market although expect tandem control-iq launch
fda approv late receiv ce mark
june user base patient unit state system
use glucos read medtron guardian sensor make basal insulin dose
decis everi five minut base compani intern develop smartguard
softwar hcl featur call auto mode user still need manual
calcul deliv bolu dose system built-in bolu wizard assist
patient estim bolu unit requir still first-gener hcl system
devic rel high guardrail believ result lower util
larg acknowledg issu mostli sensor softwar alert
burden launch softwar updat novemb design increas
user time spent oper within auto mode believ softwar updat
increas time user within auto mode approxim
given day though current user benefit updat sinc softwar
system upgrad requir new pump believ futur gener
advanc insulin pump autom bolus/bas insulin deliveri
lower daili burden associ use technolog
 tidepool loop tidepool loop third-parti hcl applic design run either
iphon watch loop ultim abl connect ace insulin
pump icgm allow patient realiz benefit hcl softwar regardless
hardwar choic loop app yet fda approv softwar
algorithm drive commerci app readili avail sever year
open-sourc solut hcl technolog today nearli patient
download loop softwar tidepool websit creat do-
it-yourself do-it-yourself solut hcl technolog although do-it-yourself loop system work
older-gener insulin pump like medtron insulet
given outdat secur softwar allow user custom
commerci loop tidepool join announc late
announc develop first fda-approv complet ecosystem compat
tidepool loop first technolog compat loop least
regulatori perspect tidepool seek autom insulin deliveri aid
approv loop app allow ace pump icgm compat
loop without need addit clinic data ultim provid patient
greater flexibl diabet manag choic believ could serv
broad tailwind insulin pump cgm adopt recent announc
next-gener insulin pump compat tidepool loop app
open histor close ecosystem tidepool softwar icgm
like eventu abbott libr eversens
tidepool recent regulatori updat suggest interim readout pivot
trial octob data enrol patient compani hope
use de novo fda submiss decemb admittedli best-cas
timelin tidepool impli loop could approv market first quarter
tidepool pivot trial part fda new pre-certif pilot program aim
streamlin approv process software-bas medic devic allow
help creat new framework aid control loop approv import
mileston diabet manag provid patient interoper pre-
fer technolog also help establish new streamlin regulatori framework
softwar approv diabet manag
margaret kaczor cfa blair tidepool loop iphon appl watch user interfac
note tidepool loop developmentit avail commerci use
iv advanc closed-loop acl system estim expect acl system next
major develop insulin pump technolog first system tandem control-iq
launch late system build capabl hcl pump introduc
new featur larg aim minim neg effect inaccur manual bolus
minim daili burden diabet manag lower manual interact
pump specif acl system still requir user calcul bolu dose
new advanc algorithm abl proactiv adjust size bolus increas
decreas dose base factor like near-term glucos predict histor insulin usag
estim carb intak also expect incorpor automat bolu correct
help reduc user daili burden greatli reduc potenti elimin need
post-meal glucos check often result anoth manual bolu calcul deliveri
note industri progress closed-loop gener expect averag
glucos level time rang improv also standard deviat glucos level
decreas closed-loop algorithm aim lower variabl glucos level ensur tighter
control improv outcom greater number user tighter band varianc user
mean improv averag glucos level new technolog algorithm
help achiev goal lower burden use improv automat dose decis
advanc pump featur main purpos automat bolu correct
improv glucos control pump user acl system next major step close
loop repres first time insulin pump abl adjust deliv auto-
mate bolus basal dose acl still consid hcl system sinc meal
announc yet option patient reach next gener pump
capabl close loop prove difficult sever compani focus initia-
tive alreadi year clinic back
tandem control-iq tandem control-iq system expect launch late
first acl system commerci avail similar tandem basal-iq control-
iq run tandem slim tube insulin pump ace design use
glucos read dexcom make insulin dose decis behalf patient
although manag may make futur icgm devic compat well note
control-iq softwar power typezero acquir incontrol algorithm
academic/clin develop sinc believ control-iq
two notabl advantag enter pump market late
first acl system control-iq take anoth step toward fulli autom insulin
dose decis allow system deliv correct bolus clinic data
admittedli yet clear benefit correct bolus control-iq time rang
similar pivot trial though perfect comparison believ
featur could help build patient trust adopt pump system
second import control-iq system meaning reduc daili
burden associ advanc pump technolog specif believ slim
color touchscreen recharg batteri waterproof design upgrad softwar
make better day-to-day user experi use dexcom allow
user elimin need fingerstick still benefit solid accuraci
reliabl togeth believ tandem control-iq one tailwind
drive next leg acceler pump adopt under-penetrated insulin-depend
 minim start pivot trial june
anticip approval/commerci launch april manag expect
system meaning upgrad minim line-up especi given
softwar hardwar upgrad plan new system
hardwar side updat five-year-old pump system includ
bluetooth connect upgrad softwar although system still lack
advanc featur like touchscreen recharg batteri use glucos
read medtron guardian sensor still requir minimum two
calibr per day compani abl secur nonadjunct label
launch otherwis requir four-plu calibr per day still manag
seek ace design pump allow user creat
hcl system tidepool iphon app dexcom sensor factori calibr
instead sensor said user need wait launch
separ strip version tidepool compat
time product launch unknown
intern develop algorithm hcl system partner
dream earli develop next-gener algorithm use
dream fine-tun acl algorithm year develop
platform power fuzzi logic adapt learn combin call
md-logic given algorithm abil make decis like doctor specif al-
gorithm intend adjust patient need timemuch like physician
wouldto improv specif user glycem control
dream algorithm expect improv auto-bas control allow
automat correct bolus reduc number closed-loop alarm increas
time oper within close loop sever small safeti feasibl tri-
al demonstr total time glucos rang mid- high although
manag believ system achiev greater real-world time rang
overal critic upgrad help close competit gap
tandem slim
omnipod horizon sever year development work guid
 launch omnipod horizon late earli system leverag insu-
let recent launch omnipod dash platform ad among featur bluetooth
connect compani patch pump pod enabl seamless com-
munic pod algorithm horizon system launch horizon
reli dexcom potenti sensor though manag intend secur
ace design horizon pump allow icgm compat
algorithm power horizon acl featur develop team research
univers california santa barbara start team form com-
pani call modeagc subsequ partner incorpor
algorithm omnipod platform conduct three trial
horizon system trial demonstr earli promis glucos control
exampl ada meet present result four day horizon use
children age two six show averag time rang time
spent hypoglycemia level control larg line competit system
especi encourag sinc particular trial cohort children
consid difficulti glucos control earli clinic data
encourag wait larger extend free live trial better assess
horizon system glucos control stack competit overal expect
horizon uniqu acl solut diabet patient despit rel late com-
mercial launch like least year behind competit
believ omnipod uniqu form factor patch pump offer patient best-in-class
comfort conveni still offer advanc pump featur
acl algorithm hous pod user abl remain within closed-
loop care even leav behind phone horizon offer samsung
phone control offer patient high level conveni compar
tube insulin pump potenti improv clinic outcom patient
remain within advanc care often second expect leverag work
pharmaci launch system channel meaning improv
market access allow patient benefit up-front pump cost less burden-
paperwork compar dme still benefit acl system
remind pharmaci channel offer sever benefit patient
first use pharmaci channel elimin up-front cost associ
pump adopt free allow patient tri omnipod limited/no-risk free
up-front also make technolog less expens patient adopt
limit impact insulet total sale estim sale less total
sale patient adopt increas shift pharmaci given
quicker timelin physician write e-prescript much easier process
dme paperwork patient pick omnipod local pharmaci
hour versu averag lag time durabl medic equip asid
elimin cost pharmaci channel less expens patient
sinc patient typic pay co-pay co-insur pharmaci usual
fraction total cost system reduc barrier acceler adopt
pump offer particularli pump acquir via
channel
 person closed-loop pcl system estim later pcl system
first time insulin pump capabl fulli close loop complet autom insu-
lin deliveri system use machin learn algorithm constantli fine-tun
decision-mak process deliv person care user uniqu need power
person machin learn algorithm pump system equip make
dose decis span small basal adjust throughout day larg bolus
follow meal exercis ultim goal pcl maintain healthi glucos rang
minim elimin need manual interact close loop meal-
time bolu announc like recommend requir system
safe close loop highli complex effort expect ultim requir
addit three year product develop although compani like
privat held beta bionic bigfoot biomed alreadi made progress front
complex elimin manual interact larg factor human bodi high
variabl respons glucos insulin dose compound need make real-
time predict decis counter reaction person uniqu respons
insulin glucos variabl driven factor demograph age race
sex etc level activ sleep walk exercis shower etc speed
individu chang activ user physiolog chang time height
illustr point bigfoot biomed present data one person glucos
respons variabl juic box specif data show uniqu
glucos respons period juic box person
trend algorithm reli autom insulin pump need abl
quickli adapt respond possibl glucos respons around snack meal time
bolus last manual process close loop requir simpli put insulin
danger drug use appropri quantiti leav littl room error
closed-loop system even seem rare occurr
sum pcl system one difficult deliv highest expect
improv glucos control given lack relianc manual input expect pcl sys-
tem one last major develop pursuit fulli closed-loop system
potenti subsequ upgrad around system usabl enhanc eas use
privat compani alreadi develop year clinic back pcl
system expect everi major pump manufactur pursu technolog
beta bionic ilet beta bionic start develop pcl algorithm earli
conduct dozen phase ii clinic trial refin valid system
compani larg focus develop bi-hormon pump system
detail plan first launch insulin-onli version ilet pump
use pcl algorithm develop sever year beta
bionic plan run insulin-onli ilet pivot trial start second quarter
hope launch system unit state earli
ilet system design maxim patient eas use softwar simplic
deliv excel glycem control regardless patient engag level
diabet care hardwar side ilet tradit tube pump use low-
power-consumpt lcd touchscreen easi clear system navig pump
run wireless recharg batteri last five day singl charg
waterproof allow addit safe wear time insulin-onli configur
ilet ship two chamber user simpli add glucagon cartridg
updat set bi-hormon care dual chamber system approv
potenti
ilet algorithm perhap differenti featur system design
meaning reduc burden diabet manag specif ilet algorithm
requir one quantit inputth user bodi weightto initi maintain
closed-loop care design elimin need patient count carbohydr cal-
culat carb-to-insulin ratio set basal bolu insulin rate throughout day
time-consum burdensom aspect diabet manag
beta bionic believ elimin step still deliv solid glycem
control use machin learn ilet constantli everi five minut adjust user
basal rate also learn store inform better control glucos
level futur bolu side mealtim announc option though
recommend achiev best possibl outcom reli qualit measur
small normal larg meal rather exact carb count
despit lack manual detail input user ilet achiev solid
clinic outcom sever phase ii trial adult adolesc base
clinic data collect far manag believ insulin-onli ilet system achiev
averag level slightli limit time spent sever hypoglycemia
mg/dl less result larg line acl system
achiev meaning less input user allow larger portion
patient benefit technolog
ilet init
user bodi weight
elimin need
ship insulin
glucagon chamber
patient use
glucagon
algorithm allow
bolu ilet ask
carb
reli qualit
descript simplifi
caution ilet investig devic limit feder law investig use
 bigfoot biomed autonomi bigfoot biomed privat compani found
though closed-loop algorithm power bigfoot ecosystem date back far
year bigfoot amass hour close loop data clinic
trial home use proof-of-concept devic help compani refin
insulin deliveri algorithm bigfoot plan leverag closed-loop algorithm launch
two product bigfoot uniti smart pen bigfoot autonomi insulin pump
bigfoot uniti pen similar smart pen avail track amount insulin
deliv smartphon app use compani algorithm give user
suggest much insulin deliv next dose compani
plan launch bigfoot uniti pen system
bigfoot autonomi compani closed-loop pump system use bigfoot person
closed-loop algorithm autom insulin deliveri decis user bigfoot pump
tradit tube insulin pump bigfoot acquir asant may bigfoot
leverag asant snap pump technolog creat system user interfac
screen diabet care done compani smartphon app
bigfoot histor use glucos read sensor clinic work
compani announc new partnership abbott libr sensor
system expect use next-gener libr sensor capabl send real-tim read-
ing user phone allow bigfoot algorithm make real-tim dose decis
behalf patient time commerci launch autonomi system
unknown though suspect bigfoot wait appropri sensor receiv approv
move forward
note bigfoot product- service-focus intend creat all-inclus
provid ship diabet manag suppli pump suppli cgm fingerstick
etc patient as-need basi one flat monthli fee manag believ
streamlin diabet care elimin need coordin sever differ
supplier creat less burdensom consumer-friendli continuum care believ
interest value-ori concept patient would interest given
current hassl diseas manag believ industri payer start
move toward subscript model though process like take time fulli
develop yet prove across diabet technolog result believ
bigfoot need negoti price payer success commerci busi
model like take time invest
 minim pcl earli announc receiv fda break-
design develop pcl pump system system
still earli develop fda submiss expect earli provid
high-level detail system system run tradit minim tube
insulin pump compat next-gen cgm sensor featur new
advanc pcl algorithm develop partnership dream
sensor expect reduc calibr requir day fingerstick
still lag behind competit factori calibr also highlight
recent acquisit nutrino health nutrient data provid integr devel-
opment pcl system expect leverag nutrino nutrient databas
fine-tun insulin decision-mak process also provid patient dietari tip
better manag glucos
tandem slim detail next-gener slim system limit manag
publicli confirm intern develop advanc pcl system
expect next-gen softwar leverag upgrad slim pump compat
multipl icgm system provid patient posit conveni user experi
vi bi-hormon closed-loop bcl system estim bcl system design im-
prove glucos control use two hormon insulin glucagon better control glucos
level specif system use insulin lower glucos level high
prevent hyperglycemia glucagon use rais glucos level
low prevent hypoglycemia ultim goal bcl system achiev better
glucos control fewer lows/high accur mimick function natur
pancrea bcl system expect closest get artifici pancrea
near futur close mimic natur function human pancrea
today development effort bcl space limit beta bionic notabl
except larg lack stabl formul glucagon minim clariti
cost glucagon clinic benefit result today pump solut reli
insulin lower glucos level form human input mostli food rais glucos
level back healthi rang expect industri remain larg focus use
insulin-onli system given patient familiar access insulin establish reimburs
polici around globe still expect attent turn bcl system stabl
formul approv believ long-term investor focus solu-
tion potenti improv clinic outcom diabet patient
beta bionic ilet beta bionic bi-hormon system expect launch
insulin-onli configur bi-hormon system foundat compani
insulin pump effort earliest clinic data date dual-chamb
ilet system yet design beta bionic earli clinic test user bionic
pancrea use two tandem slim pumpson pump insulin one pump gluca-
gonthat driven laptop hous compani closed-loop algorithm
year beta bionic refin improv bcl softwar clinic outcom
sever inpati outpati studi
beta bionic believ use glucagon meaning improv glucos control
help lower incid hypoglycemia increas time spent healthi glucos rang
lower standard deviat glucos level result bi-hormon system
expect help greater number patient achiev ada-recommend level
regardless degre patient activ manag diseas someth
arguabl help drive insulin pump adopt move target
bi-hormon ilet system achiev goal use glucagon rais glucos
level prevent hypoglycemia allow tighter rang control without need
manual intervent user beta bionic solid clinic back bi-
hormon system show time spent healthi glucos rang
mg/dl less time spent hypoglycemia outcom achiev
minim train especi compar today closed-loop system given
simplic ilet system abil initi one inputbodi weight
beta bionic expect initi pivot trial bi-hormon system fourth quarter
posit compani pma submiss late potenti approval/
commerci launch zealand pharma work toward fda approv
glucagon formulari approv bi-hormon ilet system depend
histor insulin pump gone fda regulatori pathway clearanc
sold unit state clearanc consid less stringent pathway
compar pre-market approv pma allow compani launch new pump rel
less clinical/benchmark data would requir pma pathway said closed-
loop system start requir pma approv given higher risk
profil make insulin dose decisionsrecal closed-loop system deadli much
littl insulin deliv expect futur closed-loop system minimum
show similar clinic data medtron pivot trial tandem control-iq pivot trial
larg establish regulatori pathway closed-loop system
margaret kaczor cfa blair specif compani ran rel larg trial patient trial
patient control-iq pivot trial extend follow-up period three- six-month
studi period control-iq begin trial enrol medtron
took approxim month receiv pma approv estim line tandem
guidanc control-iq take month receiv pma approv regulatori
pathway outlin follow exhibit believ like minimum require-
ment pma approv note futur gener closed-loop product could possibl
requir data go beyond capabl today system bi-hormon system
even elimin receiver/pdm
approxim month approv
data submit fda
sourc clinicaltri gov
approxim month approv
data submit fda
sourc clinicaltri gov
margaret kaczor cfa blair implic
though believ number compani benefit acceler market growth associ
next-gener pump technolog specif highlight impact look
forward continu expect primari beneficiari grow market demand
insulin pump given on-going launch next-gen system omnipod dash uniqu wearabl
form factor expans pharmaci channel improv market access
latter particular pharmaci channel uniqu game changer diabe-
te care provid benefit nearli stakehold involvedpati doctor payer
alik patient pharmaci access lower barrier adopt elimin
up-front cost adopt free lower cost on-going pump use reli
pharmaci co-pay may less expens tradit dme cost doctor expect
streamlin process pharmaci product versu dme product meaning reduc
paperwork ultim even increas rate doctor recommend prescrib
omnipod patient give omipod dash new patient free also help-
ing lower financi burden pump adopt payer help improv coverag
market access lastli secur coverag pharmaci channel expect
compani abl realiz oper leverag amount still determin
realiz benefit less burdensom shorter less paperwork prescript pathway
given potenti acceler new patient add likelihood tech-
nolog advanc acceler adopt pump broadli analyz current
estim sever scenario base scenario analysi believ
compani could deliv million increment domest sale current
estim line guidance/consensu publish model
analysi suggest could acceler year-over-year domest sale growth
percentag mid- high given recur natur busi
model new patient add extent would compound deliv addit
upsid sale estim
translat impact better-than-expect domest sale total compani result sale
growth would come rang basi point
publish estim sale would come million versu
million sale would come billion versu mil-
lion note valu assum upsid intern drug deliveri
run assumpt scenario analysi subsequ
impact domest oper sale growth
base casecurr estim base case scenario base current estim
low high-teen sale growth line guidance/consensu rel
stabl market growth approxim scenario estim new patient
add make approxim new insulin pump user next
three year larg line estim made new
pumper year assum remain larg driver pump market
adopt see increment benefit rel peer recent result despit
next-gen system improv market access
scenario believ could deliv upsid acceler pump market
growth captur patient come sidelin
previous mention market growth larg line histori-
cal midsingle- high-single-digit growth could prove conserv new technolog
increas awar insulin pump drive market demand may abl
captur new pumper benefit differenti wearabl form factor
improv market access pharmaci channel
acceler approxim
respect growth out-year acceler market
experienc mani year impli deceler total new pumper growth
specif scenario impli pump market add increment patient
repres growth add
patient year-over-year basi respect given tailwind insulin
pump market growth outlin report believ estim could achiev
lay bull case look market develop second half
bull case assum captur new pumper annual larg line
base case scenario assum
first bull case scenario impli revenu growth come basi
point current estim would achiev domest
sale million million million add
respect new patient exhibit highlight scenario
bull case market growth share gain second bull case scenario
assum elev pump market growth assum larger driver
market adopt new patient driven uniqu go-to-market strategi product
pipelin case model captur new pump user year
prior scenario increas recent year would suggest
benefit insulet on-going shift pay-as-y go model/pharmaci access pipe-
line product dash horizon
scenario impli revenu growth acceler basi point
current estim result would achiev domest sale
million million million add respect
new patient
estim steadi pump
market growth
acceler
growth
captur new patient
line base case
bull case
captur new patient
appendix chang estim
chang estim introduc estim
third quarter revenu estim million remain unchang ep
estim remain unchang
fourth quarter revenu estim million remain unchang ep
estim remain unchang
full year revenu estim million remain unchang ep esti-
mate remain unchang
full year revenu estim increas million million
ep estim increas
full year introduc revenu estim million ep estim
chang estim introduc estim
third quarter revenu estim increas million million
ep estim increas
fourth quarter revenu estim increas million million
ep estim decreas
full year revenu estim increas million million
ep estim unchang
full year revenu estim increas million million
ep estim increas
full year introduc revenu estim million ep estim
appendix addit detail notabl closed-loop insulin
overview receiv fda approv first-ev hcl system minim sep-
tember focus initi commerci effort exist user base allow
patient upgrad prioriti access program also use
control launch period time invest cgm manufactur support meaning-
fulli higher sensor output meet demand full-scal launch start late
ramp juli instal base
user provid million patient day diabet manag data
plan leverag next-gener technolog
compon entir compos compon includ min-
ime pump guardian sensor smartguard softwar key compon
minim pump minim pump stapl diabet busi
first launch year ago sever updat system
past decad current line pump first introduc seen
minor updat sinc pump tradit tube pump use cannula infus
set deliv insulin featur small led screen tactil button navig softwar
user interfac pump waterproof water resist feet use
tradit aa batteri recharg batteri last day lastli
pump softwar upgrad mean histor upgrad
hardwar replac entir pump roll new softwar featur
guardian sensor medtron guardian sensor cgm compat
system regulatori technolog standpoint requir patient use
auto mode closed-loop featur guardian compris sensor last seven day
recharg transmitt last seven day receiv guardian sensor
rel accur mard depend locat sensor wear
system lag behind competit system featur specif guardian sensor still
requir least two fingerstick calibr per day real-world feedback suggest even
calibr sensor wear time seven day shorter competit cgm
approv nonadjunct devic mean user suppos make insulin
dose decis base read
smartguard algorithm develop softwar system
build past featur like low glucos suspend also introduc system hcl featur
call auto mode auto mode softwar read user glucos levels/trend
cgm determin adjust user appropri basal rate tri keep
patient target glucos level mg/dl auto mode reli proport integr
deriv pid logic mean system react rather predict measur
glucos level pivot trial abl keep patient within healthi glucos
rang mg/dl time adult adolesc
overview tandem expect receiv fda approv hcl softwar control-iq end
expect slim second hcl system commerci avail second
market believ offer import improv medtron specif
believ slim meaning improv eas use turn complianc intui-
tive touchscreen pump factory-calibr reliabl cgm advanc hcl softwar
capabl deliv automat bolu correct tandem expect make control-iq avail
exist slim user base cost via softwar upgrad plan offer futur pump
new hcl featur preinstal tandem present posit data control-iq pivot
trial ada meet patient stay healthi glucos rang time
closed-loop system activ time
compon tandem partner typezero own
integr cgm algorithm technolog tandem slim insulin pump hcl
softwar integr slim pump although patient need also purchas dex-
com cgm use hcl featur
tandem slim tandem slim pump tradit tube insulin pump
first approv unit state late slim classifi fda
ace pump mean system compat regulatori standpoint
icgm aid algorithm pump offer patient enhanc user experi
featur like color touchscreen smaller pump size compar competitor built-in
bluetooth technolog interoperability/integr recharg batteri perhap
mani featur help improv daili interact patient insulin
deliveri technolog offer upgrad softwar allow tandem incorpor new
featur pump without replac entir pumpa meaning improve-
ment patient typic lock four- five-year pump reimburs cycl
insur provid august tandem receiv approv slim integr
dexcom sensor subsequ roll product user base cost
softwar updat june tandem receiv approv basal-iq featur
predict low-glucos suspend offer featur slim user base
cost import patient histor wait could
purchas new pump benefit innov field control-iq hcl featur
roll similar way
icgm primari cgm partner hcl system outsid
medtron ecosystem commerci avail hcl system use
today previou iter cgm use extens hcl trial believ
dexcom heavili reli accuraci steadi cadenc innov eas
use willing partner player system compris sensor last
day transmitt last three month receiv although cgm
control directli smart phone system factori calibr elimin
need fingerstick calibr approv nonadjunct use make insulin
decis base real-tim read believ meaning enhanc
patient greatli reduc burden cgm technolog benefit carri
daili use tandem hcl lower daili burden hcl technolog associ
typezero incontrol tandem control-iq tandem licens typezero incontrol platform
sinc integr algorithm slim pump call hcl featur
control-iq typezero incontrol develop decad start
academ research project univers virginia typezero start in-human trial
incontrol system gather nearli hour clinic trial hour
differ patient allow typezero refin improv autom insulin deliveri
algorithm given typezero extens experi develop hcl algorithm sever
compani also licens incontrol platform includ roch eoflow
recent acquir typezero hope leverag incontrol platform futur hcl system
cgm devic featur like predict low glucos alert
technic side incontrol platform base model predict control
algorithm predict glucos level minut ahead adjust basal rate poten-
tialli bolus keep patient within target rang mg/dl target rang
purpos narrow recommend glucos rang mg/dl provid
time buffer insulin react exampl incontrol predict user glucos level
drop mg/dl next minut pump automat suspend slow
insulin deliveri vice versa increas insulin high end target rang
control-iq pivot trial patient remain healthi glucos rang
time remain within closed-loop system time import note
incontrol abil deliv correct bolus believ user miscalcul
carb expect help patient remain within target glucos rang
overview began develop omnipod horizon system earli licens
autom glucos control llc modeagc hcl algorithm integr omnipod
omnipod dash omnipod dash latest patch pump platform build origin
tubeless waterproof form factor ad touchscreen person diabet manag
upgrad pod notabl bluetooth connect omnipod dash enter full
commerci launch first quarter laid foundat horizon hcl system
introduct bluetooth connect plan file approv omnipod
dash platform ace design pump would allow interoper omnipod
horizon fda-approv icgm sensor aid algorithm time
believ omnipod horizon offer uniqu form factor diabet manag
tubeless patch pump hcl capabl insulin deliveri algorithm
hous pod patient remain within hcl even away
smartphon devic help lessen daili burden diabet manag fewer
devic carry/manag potenti improv clinic outcom patient spend
time within hcl system target glucos rang overal expect horizon
differenti solut hcl landscap given wearabl patch form factor
icgm insulet primarili use sensor horizon clinic
trial plan file approv horizon system dexcom still expect
horizon compat regulatori standpoint icgm devic given man-
agement guidanc seek ace pump design previous highlight compris
sensor last day transmitt last three month durabl
receiv factory-calibr approv nonadjunct use believ
meaning enhanc patient greatli reduc burden cgm technolog
use dexcom horizon system repres competit advantag
modeagc horizon enter licens agreement modeagc earli
develop integr hcl algorithm omnipod platform partnership
modeagc meaning step toward develop omnipod hcl system
sinc provid eight year research develop hcl algorithm
modeagc algorithm first publish credit research univer-
siti california santa barbara gone sever iterations/publ
research refin system improv glucos control
ilet dual-chamb pump ilet gone multipl iter last sever
year beta bionic refin devic make intuit safe conveni
user pump fourth gener system manag intend launch
commerci unit state beta bionic intern develop ilet system partli
focu creat dual-chamb system capabl deliv insulin
glucagon one devic compani develop develop one leav beta
bionic creat solut
ilet similar tradit tube insulin pump use cannula deliv hormon
patient system two chamber one insulin one glucagon
beta bionic creat new dual-chamb cannula uniqu design patent
connector ensur patient insert insulin cartridg insulin chamber
plug insulin cannula insulin port vice versa glucagon critic
safeti usabl featur dual hormon pump sinc deliveri wrong hormon
properli treat patient even exacerb unhealthi glucos level sinc
hormon serv opposit purpos exampl insulin accident deliv patient
in/approach low glucos level send patient even lower glucos level
extrem case kill patient ilet ship dual-chamb configur
begin commerci beta bionic first seek approv insulin-onli
version second chamber unus simpli cover plastic cap
ship system dual-chamb configur manag hope ilet user
abl use glucagon approv one two year later without purchase/
upgrad pump
pump similar size tube pump featur touchscreen low-energi
led screen maxim batteri life five day one charg batteri re-
chargeabl elimin cost replac batteri use induct wireless charg
much like appl watch user interfac ilet softwar design intuit
easi use make system access age group level technolog prowess
degre diabet manag lazi activ patient one way system
achiev goal elimin need calcul system use
number patient ever need enter stay within closed-loop care weight
first initi system detail software/algorithm
icgm beta bionic larg reli clinic trial
intend ilet system compat dexcom launch beta bionic
plan seek ace design ilet allow system run icgm devic
regulatori standpoint eventu open system greater interoper
patient remind dexcom compris sensor last day transmitt
last three month durabl receiv factory-calibr approv
nonadjunct use ilet slate late earli believ
icgm approv unit state beta bionic like incorpor
softwar expect abbott libr receiv icgm approv sometim dex-
com launch sometim late earli although time senseon
eversens icgm approv unknown expect compani seek icgm approv well
beta bionic algorithm ilet person closed-loop algorithm develop-
ment decad initi effort start clinic trial start
outset beta bionic team focus creat system requir
one inputbodi weightand simpl enough age group level diabet
manag word beta bionic long focus creat algorithm simpl
enough broad-bas use among insulin-depend patient will deal
daili burden tradit pump usag
reli user bodi weight ilet elimin need patient make
calcul either start-up regular use user enter bodi weight
system advanc algorithm determin proper paramet without need
manual intervent user physician beta bionic believ system eas use
appeal diabet patient also support improv clinic outcom
better glycem control increas amount time patient remain within close loop
within mathemat optim care paramet rather manual adjust made
period physician manag believ algorithm achiev ada-recommend
level user use dual-hormon configur compar
favor today hcl system demonstr averag level near recommend
level still leav approxim patient goal
note beta bionic algorithm also use patient glucos histori refin dose decis
time result patient use ilet system person insulin
dose decis becom improv glycem control algorithm base
treat-to-target logic target chosen softwar initi rather
treat-to-rang logic beta bionic hope use treat target especi use
dual-hormon configur help lower standard deviat glucos movement
improv time rang improv clinic outcom
margaret kaczor cfa blair price common stock public compani mention report follow
